<DOC>
	<DOCNO>NCT01212107</DOCNO>
	<brief_summary>The study determine recommend Phase 2 regimen study drug may safely administer patient advanced metastatic cancer . The study consist two part : dose escalation dose confirmation .</brief_summary>
	<brief_title>A Study LY2874455 Patients With Advanced Cancer</brief_title>
	<detailed_description>Phase 1 , first human dose study</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer ( solid tumor , lymphoma , chronic lymphocytic leukemia ) advance and/or metastatic standard therapy fail Have presence measurable nonmeasurable disease Have give write informed consent prior studyspecific procedure Have adequate organ function include : Hematologic : Absolute neutrophil count ( ANC ) equal great 1.5 x 10 ( 9 ) /L platelet equal great 100 x 10 ( 9 ) /L , hemoglobin equal great 8 g/dL . Patients may receive erythrocyte transfusion achieve hemoglobin level discretion investigator . Initial treatment must begin 14 day erythrocyte transfusion Hepatic : Bilirubin equal le 1.5 time upper limit normal ( ULN ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) equal less 2.5 time ULN . If liver tumor involvement , AST ALT equal equal le 5 time ULN acceptable Renal : Serum creatinine less equal 1.2 time ULN calculate creatinine clearance great equal 60 milliliter per minute use Standard Cockcroft Gault Creatinine Clearance Calculation Calcium phosphate le equal 1.1 time ULN Have performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue chemotherapy cancerrelated hormonal therapy commercially available agent least 21 day ( 6 week mitomycinC nitrosoureas ) radiotherapy least 14 day prior study enrollment recover acute effect therapy . Hormone refractory prostate cancer patient receive gonadotropin release hormone ( GnRH ) agonist therapy breast cancer patient antiestrogen therapy ( example , aromatase inhibitor ) prior entrance study may treatment continue enrol study Females childbearing potential must negative serum pregnancy test less equal 7 day prior first dose study drug . Males females reproductive potential must agree use 2 medically approve contraceptive method trial 3 month follow last dose study drug . Female patient must agree use 2 medically acceptable method contraception , 1 oral contraceptive , dermal patch , progestin ( implantation injection ) , medically acceptable barrier method ; alternatively , 2 medically acceptable barrier method may use . Medically acceptable barrier method contraception may use participant and/or his/her partner include : abstinence ; diaphragm spermicide ; intrauterine device ( IUD ) ; condom together foam , spermicide , vaginal spermicidal suppository . Prohibited method include rhythm method , withdrawal , condoms alone , diaphragm alone Have estimate life expectancy great equal 12 week Have receive treatment investigational drug , receive regulatory approval indication , within 28 day study treatment LY2874455 Currently take agent control serum phosphate calcium level . This include dietary restriction Have medical condition , opinion investigator , would preclude participation study Have symptomatic central nervous system ( CNS ) malignancy metastasis . Patients treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , currently receive corticosteroid and/or anticonvulsant . Screening asymptomatic patient without history CNS metastasis require Have history major organ transplant ( example : heart , lung , liver , kidney ) Have current acute leukemia Females pregnant nursing An untreated uncontrolled acute infection , include urinary tract infection , within 7 day study entry Have Bazett 's correct QT ( QTcB ) great 470 msec ( female ) great 450 msec ( male ) , history unexplained recurrent syncope , history congenital long QT syndrome , family history sudden death , presence screen electrocardiogram ( ECG ) conduction abnormality opinion investigator would preclude safe participation study Have autologous allogenic bone marrow transplant Previously treat LY2874455</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Oncology</keyword>
</DOC>